stockportfolio.pro
Stocks / RLMD vs SIBN
RLMD vs SIBN
Relmada Therapeutics, Inc. and SI-BONE, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Relmada Therapeutics, Inc. (RLMD) | SI-BONE, Inc. (SIBN) | |
|---|---|---|
| Market cap | $0.7B | $0.7B |
| Revenue (latest FY) | $0 | $200.93M |
| Net income (latest FY) | $-57.39M | $-18.90M |
| Revenue growth (5y CAGR) | — | 22.3% |
| Net margin | — | -9.4% |
| Return on equity | -66.3% | -10.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | — | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open RLMD — free Open SIBN — freeFrequently asked questions
Which is bigger, RLMD or SIBN?
SI-BONE, Inc. is larger by market capitalization — $0.7B versus $0.7B.
Which grows faster, RLMD or SIBN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.